文献速递细菌感染、耐药与抗菌药物医院感染防控

BALANCE试验事后分析:未依从既定抗生素疗程对血流感染结果的影响

Accounting for non-adherence to assigned antibiotic treatment duration for bloodstream infection (BALANCE): a post-hoc analysis of a randomised clinical trial.
PubMed 文献 · Lancet Infect Dis · 2025-11-11

BALANCE试验显示,对非金黄色葡萄球菌非复杂性血流感染,7天抗生素疗程不劣于14天。采用因果推断方法校正未依从所致偏倚后,7天疗程不劣于14天的结论保持一致,支持将7天疗程作为非复杂性血流感染的标准治疗。

要点

  • 非复杂性血流感染7天抗生素疗程不劣于14天。
  • 校正未依从偏倚后,7天疗程不劣于14天的结论不变。

核心结论

  • 校正未依从所致偏倚后,7天抗生素疗程治疗非复杂性血流感染不劣于14天疗程的结论保持一致。

研究设计与样本

  • BALANCE随机临床试验(NCT03005145)的事后分析,纳入3581例有完整结局数据的患者。
  • 采用广义线性混合模型识别与未依从相关的因素。
  • 采用逆概率治疗加权(IPTW)和工具变量法,在校正后的符合方案集和接受治疗集(两种依从性定义)中估计疗程对90天全因死亡率的影响。
  • 沿用BALANCE试验的4%非劣效界值判定7天疗程的非劣效性。

主要发现

  • 疾病严重程度、腹腔感染源、皮肤或软组织感染源、持续发热和持续菌血症与疗程延长相关。
  • 血管导管感染源和抗菌药物耐药与疗程缩短相关。

关键数值与推荐

  • 依从性定义为实际接受抗生素疗程较既定疗程延长或缩短不超过2天。
  • 主要结局为90天全因死亡率,非劣效界值为4%。
  • 各校正分析的风险差估计值均与BALANCE主要结果相似,且置信区间下限未超过4%非劣效界值。

临床怎么用

  • 非复杂性血流感染(非金黄色葡萄球菌)可采用7天抗生素疗程作为标准治疗。
  • 对于疾病严重、腹腔或皮肤软组织感染源、持续发热或持续菌血症者,临床可能倾向于延长疗程。
  • 血管导管感染源或存在抗菌药物耐药者,临床可能倾向于缩短疗程。

局限性

  • 本研究为随机试验的事后分析,未依从因素分析为观察性关联。
  • 未依从的定义基于研究人员的每日评估和总疗程记录,可能存在测量偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The BALANCE trial (NCT03005145) showed non-inferiority of 7-day versus 14-day antibiotic duration for treatment of patients with non-Staphylococcus aureus uncomplicated bloodstream infection (BSI). Non-adherence to assigned duration occurred in 728 (20·3%) of 3581 patients. This post-hoc analysis aimed to identify factors associated with this non-adherence, and evaluate its effect on validity of trial results. METHODS: We identified factors associated with non-adherence using generalised linear mixed models. Adherence was defined as receiving antibiotic duration up to 2 days longer or shorter than assigned duration, measured using a trial-specific adherence variable (assessed daily by research staff) and a separate variable capturing total antibiotic duration. We estimated the effect of antibiotic duration on the primary outcome of 90-day all-cause mortality, accounting for confounding introduced by non-adherence, in adjusted per-protocol and as-treated populations (using two different adherence definitions: first, using an adherence variable as assessed daily by site research staff, and second, using a total antibiotic duration variable recording the total cumulative antibiotic duration received), using inverse probability of treatment weighting (IPTW) and instrumental variable methods. We compared these adjusted estimates to the primary effect estimates in BALANCE and used the same 4% non-inferiority margin to determine non-inferiority of 7-day duration. FINDINGS: 3581 patients with complete outcome data were included. Non-adherence was higher in the 7-day group (432 [24·0%] of 1802 patients) versus 14-day group (296 [16·6%] of 1779). Disease severity, intra-abdominal and skin or soft tissue source of infection, persistent fever, and persistent bacteraemia were associated with treatment prolongation, whereas vascular catheter source and antimicrobial resistance were associated with treatment shortening. Adjusted risk differences for the primary outcome of 90-day all-cause mortality were similar to the primary results in BALANCE: (1) IPTW per-protocol analysis (definition one): -1·61% (95% CI -4·13 to 0·87); IPTW per-protocol analysis (definition two): -1·91% (95% CI -4·61 to 0·93); and IPTW as-treated analysis: -0·75% (95% CI -3·36 to 1·86); and (2) instrumental variable analysis (definition one): -2·68% (95% CI -6·65 to 1·29) and instrumental variable analysis (definition two): -2·80% (95% CI -5·98 to 0·37). INTERPRETATION: Non-adherence in BALANCE was significantly associated with a range of important prognostic factors, which might have introduced bias. Causal inference methods addressing this bias showed a consistent conclusion of non-inferiority, strengthening the validity of this finding. 7-day antibiotic duration should be the standard of care for patients with uncomplicated BSI. FUNDING: The BALANCE trial was funded by the Canadian Institutes of Health Research, Health Research Council of New Zealand, Australian National Medical Research Council, Physicians Services Incorporated Ontario, and Ontario Ministry of Health and Long-term Care Innovation Fund.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Ong SWX, Pinto R, Mahar RK, et al. Accounting for non-adherence to assigned antibiotic treatment duration for bloodstream infection (BALANCE): a post-hoc analysis of a randomised clinical trial. Lancet Infect Dis. 2025. PMID: 41237792. doi:10.1016/S1473-3099(25)00592-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。